Skip to main content
Funded Studies

LRRK2 Safety Initiative

This grant builds upon the research from a prior grant: Pre-clinical Safety Study of LRRK2 Inhibitors

Study Rationale:
Previous pre-clinical work with Genentech, Inc. has demonstrated that LRRK2 kinase inhibitors may induce abnormal findings in the lungs. This study will determine if this result is due to those specific compounds or if targeting LRRK2 is a safety liability.

Is inhibition of LRRK2 safe in pre-clinical models?

Study Design:
Several potent and selective LRRK2 kinase inhibitors from different pharmaceutical companies will be chronically dosed in a pre-clinical model and peripheral organs, especially the lungs, will be evaluated for any abnormalities.

Impact on Diagnosis/Treatment of Parkinson's disease:
These exploratory toxicity studies will be crucial in determining if LRRK2 kinase inhibitors are viable therapeutics to be tested in humans.

Next Steps for Development:
A negative toxicity finding will allow for further development of LRRK2 kinase inhibitors in the clinic. If we confirm that multiple LRRK2 kinase inhibitors are a safety liability, we will follow up with more studies to understand the mechanism of action.


  • Stephen A. Ploch, PhD

    Madison, WI United States

Discover More Grants

Search by Related Keywords

Within the Same Program

Within the Same Funding Year

We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.